569 related articles for article (PubMed ID: 18336612)
1. Early results of bladder-cancer screening in a high-risk population of heavy smokers.
Steiner H; Bergmeister M; Verdorfer I; Granig T; Mikuz G; Bartsch G; Stoehr B; Brunner A
BJU Int; 2008 Aug; 102(3):291-6. PubMed ID: 18336612
[TBL] [Abstract][Full Text] [Related]
2. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
Moonen PM; Kiemeney LA; Witjes JA
Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
[TBL] [Abstract][Full Text] [Related]
3. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection.
Lotan Y; Shariat SF;
BJU Int; 2008 Jun; 101(11):1362-7. PubMed ID: 18284410
[TBL] [Abstract][Full Text] [Related]
4. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
6. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
Parekattil SJ; Fisher HA; Kogan BA
J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
[TBL] [Abstract][Full Text] [Related]
7. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
[TBL] [Abstract][Full Text] [Related]
8. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.
Huber S; Schwentner C; Taeger D; Pesch B; Nasterlack M; Leng G; Mayer T; Gawrych K; Bonberg N; Pelster M; Johnen G; Bontrup H; Wellhäusser H; Bierfreund HG; Wiens C; Bayer C; Eberle F; Scheuermann B; Kluckert M; Feil G; Brüning T; Stenzl A;
BJU Int; 2012 Sep; 110(5):699-708. PubMed ID: 22313585
[TBL] [Abstract][Full Text] [Related]
9. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker.
Lotan Y; Elias K; Svatek RS; Bagrodia A; Nuss G; Moran B; Sagalowsky AI
J Urol; 2009 Jul; 182(1):52-7; discussion 58. PubMed ID: 19450825
[TBL] [Abstract][Full Text] [Related]
10. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection.
Lotan Y; Capitanio U; Shariat SF; Hutterer GC; Karakiewicz PI
BJU Int; 2009 May; 103(10):1368-74. PubMed ID: 19338566
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
[TBL] [Abstract][Full Text] [Related]
12. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
13. Screening for bladder tumours in men aged 60-70 years with a bladder tumour marker (UBC) and dipstick-detected haematuria using both white-light and fluorescence cystoscopy.
Hedelin H; Jonsson K; Salomonsson K; Boman H
Scand J Urol Nephrol; 2006; 40(1):26-30. PubMed ID: 16452052
[TBL] [Abstract][Full Text] [Related]
14. NMP22 BladderChek Test: point-of-care technology with life- and money-saving potential.
Tomera KM
Expert Rev Mol Diagn; 2004 Nov; 4(6):783-94. PubMed ID: 15525221
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
16. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
17. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
[TBL] [Abstract][Full Text] [Related]
18. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer?
Bollmann M; Heller H; Bánkfalvi A; Griefingholt H; Bollmann R
BJU Int; 2005 Jun; 95(9):1219-25. PubMed ID: 15892805
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
Kitsukawa S; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T; Matsumoto T; Aizawa T; Noda K; Ito T
Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
